Newsletter Subject

Daily Headlines: Happier Dads, Better Adjusted Kids

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Mon, Nov 28, 2016 12:13 PM

Email Preheader Text

Daily Headlines November 28, 2016 [Non-Small Cell Lung Cancer @POC |Grant] [Multiple Myeloma @POC|Gr

Daily Headlines November 28, 2016 [Happier Dads, Better Adjusted Kids] [6 Take Homes from Liver Meeting] [Pearls From: Kim Williams, MD] [Nursing Student Diary: 12-Hour Shifts Begin] [Top Reads in Slow Medicine] Additional Resources [Diagnosis and Treatment of Relapsed Myeloma] [AML: Beware of Pre-leukemic Clones Surviving Chemotherapy] [Boosting Lung Cancer Outcomes in Diabetics] Industry Resources [Site For Endocrinologists Low Testosterone Due To Certain Medical Conditions. Treatment Info.] [T2D Treatment Information HCPs - Learn About A Treatment For Adults With Type 2 Diabetes Today.] [Myelomatosis A Treatment Option For Previously Treated Multiple Myeloma. HCP Site.] Recent Headlines [How to Deal With Workplace Conflict] [Transaortic TAVR Best Alternative to Transfemoral Access?] [Common Drugs Boost Diabetes Risk in RA Patients] CME/CE [5 Highlights from ACAAI Meeting] [Extra-Clinical Relationships With Computers] ADVERTISEMENT This Week's Survey [Are Patients Worrying About Their Health Insurance?] [Republicans have promised to repeal Obamacare and have also proposed making big changes to Medicare.] CME Spotlights [Chronic Lymphocytic Leukemia w/ Watson @POC] [Source: @Point of Care] [Non-Small Cell Lung Cancer (NSCLC) @POC (WATSON)|Grant] [Source: @Point of Care] [Clinical Context: Multiple Myeloma] [Source: Projects in Knowledge, Inc.] [Multiple Myeloma (MM) @POC|Grant|App] [Get Multiple Myeloma @Point of Care, support platform for multiple myeloma diagnosis, treatment & managementrnSource: @Point of Care] [Prostate Cancer @POC] [Source: @Point of Care] [Managing the Patient with Metastatic Melanoma: A Comprehensive, Evidence-Based Approach] [Source: Robert Michael Educational Institute LLC (RMEI)] [Immuno Oncology] [Source: @Point of Care] [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Initial Visits] [Source: Robert Michael Educational Institute LLC (RMEI)] [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Follow-up Visits] [Source: Robert Michael Educational Institute LLC (RMEI)] [Biosimilars--Can you explain extrapolation? Interchangeability? Substitution?] [Source: France Foundation] [Playing The Offense In Advanced Basal Cell Carcinoma: A Team Approach To Treatment And Management] [Source: RMEI] [MDS and Acute Myeloid Leukemia (MDS and AML) @POC] [Source: Projects in Knowledge, Inc.] [Skin Cancers@Point of Care] [Source: @Point of Care] [Gynecologic Cancers @POC] [Source: @Point of Care] [Clinical Context: Prostate Cancer] [Source: Projects in Knowledge, Inc.] [Breast Cancer@POC w/Watson] [Source: Projects in Knowledge, Inc.] More of Today's Stories [Investing in a 'Seven-Generation' Health Care Strategy] [Video Round-Up: The Best of AHA 2016] [PCMH Patients More Likely to Use Meds as Directed] [6 Highlights from Kidney Week 2016] ['Dreamland' Author Takes an Opioid Epidemic Trip] [Sarilumab Effective in RA After Failure of Anti-TNF Therapy] CME/CE [PodMed: A Medical News Roundup From Johns Hopkins] [Preventing Surgeon Burnout] [ACR 2016: Treatment Advances Continue] [Selfie Fatalities: That's Improbable!] More news from MedPage Today® Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. © 2016 Medpage Today, LLC. All rights reserved. Use of this site constitutes acceptance of the [MedPageToday.com] [terms of use] and [privacy policy]. The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Medpage Today is located at 345 Hudson Street, New York, NY 10014 [Remove me from this list] [Manage my e-mail settings]

Marketing emails from medpagetoday.com

View More
Sent On

02/07/2024

Sent On

02/07/2024

Sent On

02/07/2024

Sent On

01/07/2024

Sent On

01/07/2024

Sent On

01/07/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.